Basically either . The stock is now trading at the price it jumped to immediately after positive results of their ' female viagra ' drug bremelanotide . It is used for treatment of hypoactive sexual desire disorder . These were phase 3 results so it is now on route for regulatory approval in 2017 . Price is rising on speculation of buyout or licensing . Why do I like it ? Positive phase 3 endpoint results , their competitor at Valeant addyi has been very disappointing . Why is this different ? Addyi should not be taken with alcohol and it has more side effects . Bremelanotide is safer and CAN be taken even if alcohol has been used . It bounced to the high 60 s to low 80 s the day of the announcement of results and many people took profits , leading to a drop all the way back to predata levels ! ! These were positive results for a drug superior to the one valeant bought for $ 1 billion . If ought out or partnered , looking for $ 3 So if you believe this drug will be bought or licensed , it is not too late to enter . My cost basis is 0 . 50 but I may increase my positions . Nonetheless , it is a speculative play ! So high risk . Please be aware . I ' m making an educated guess but it could flop .